![]() |
市场调查报告书
商品编码
1494349
欧洲可流动止血剂市场预测至 2028 年 - 区域分析 - 按材料、产品、应用和最终用户Europe Flowable Hemostats Market Forecast to 2028 - Regional Analysis - by Material, Product, Application, and End User |
欧洲可流动止血剂市场预计将从2022年的2.1554亿美元成长到2028年的3.2823亿美元。
医院和手术中心数量的增加推动了欧洲可流动止血剂市场
在已开发地区和新兴地区,医院和外科中心的数量正在迅速增加。这种增长加速了新成立的手术中心和医院对手术设备(包括医疗器械和止血产品)的需求。 2020年10月,英国首相宣布计划投资约43亿美元设立40家医院,并製定到2030年为48家医院提供未来资助的计划。机会。近年来,医疗保健产业经历了快速转型。全球各国都青睐医疗保健领域的先进技术。随着对更好的医疗保健设施的需求,技术支援的护理 (TEC) 解决方案正在医疗保健系统中被提及,特别是在新兴经济体中。一些主要因素,例如慢性病发病率上升、人口老化和儿科护理等,正在帮助推动医疗保健产业的成长。随着技术程序的不断进步,局部止血剂的有效性可能有助于改善临床结果。因此,理想的局部止血剂将提供真实且快速的出血控制。医院和手术中心数量的如此显着增长需要大量采用可流动止血剂产品,最终为未来几年的市场成长提供利润丰厚的成长机会。
欧洲可流动止血剂市场概况
欧洲流动止血剂市场遍及德国、英国、法国、义大利、西班牙和欧洲其他地区。由于外科手术数量的增加、政府措施的增加、医疗保健支出的增加以及其他几个因素,预计该区域市场从 2022 年到 2028 年将稳定成长 7.3%。德国拥有一些特定的医疗设施和训练有素的医生来治疗世界各地的患者。此外,该国拥有最先进的医疗培训设施,医生需要接受广泛的教育、住院医师和实践。根据德国联邦统计局的研究,2020 年该国拥有近 951,936 名医院工作人员和约 1,903 家医院,预计未来几年该国的手术数量将增加。外科手术数量的增加是德国止血剂市场成长的关键因素。例如,根据德国胸腔心臟血管外科学会 (GSTCVS) 的数据,2019 年全国註册手术量约为 161,817 例,其中 92,809 例为心臟手术。此外,德国是最大的医疗技术市场,在国际上排名第三。该国生产约 11,000 种医疗器械,三分之二的医疗器材销售是在国内市场以外生产的。德国拥有 30 多个致力于创新医疗技术的专用集群网路。德国政府 2020 年国家高科技战略是一项广泛的跨部门推动策略。因此,医院数量的增加和手术数量的增加等因素可能会在预测期内推动该市场的发展。
欧洲可流动止血剂市场收入及 2028 年预测(百万美元)
欧洲流动止血剂市场细分
欧洲流动止血剂市场分为材料、产品、应用、最终用户和国家。
根据材料,欧洲流动止血剂市场分为牛明胶和猪明胶。到 2022 年,牛明胶细分市场将在欧洲流动止血剂市场中占据更大份额。
就产品而言,欧洲可流动止血器市场分为组合止血器、被动止血器和主动式止血器。到 2022 年,组合止血剂细分市场在欧洲流动止血剂市场中占据最大份额。
根据应用,欧洲可流动止血剂市场分为一般外科、心臟外科、血管外科、骨科外科、神经和脊椎外科等。 2022 年,一般外科细分市场在欧洲流动止血剂市场中占最大份额。
根据最终用户,欧洲可流动止血剂市场分为医院和诊所、门诊手术中心等。 2022 年,医院和诊所领域在欧洲流动止血剂市场中占最大份额。
依国家/地区划分,欧洲流动止血剂市场分为德国、英国、法国、义大利、西班牙和欧洲其他地区。 2022 年,德国在欧洲流动止血剂市场占据主导地位。
Baxter International Inc、Ethicon (Johnson & Johnson)、Pfizer Inc、Teleflex Incorporated、3-D Matrix Medical Technology、Biom'up 和 Aegis Lifesciences 是欧洲流动止血剂市场上的一些领先公司。
The Europe flowable hemostats market is expected to grow from US$ 215.54 million in 2022 to US$ 328.23 million by 2028. It is estimated to grow at a CAGR of 7.3% from 2022 to 2028.
Increasing Number of Hospitals and Surgical Centers Fuel Europe Flowable Hemostats Market
The number of hospitals and surgical centers is increasing rapidly in developed and emerging regions. Such growth accelerates demand for surgical equipment (including medical devices and hemostat products) for lately established surgical centers and hospitals. In October 2020, the Prime Minister of the UK announced plans to invest around US$ 4.3 billion for the setting of 40 hospitals and a scheme for future funding for 48 hospitals by 2030. Furthermore, the growth in the healthcare sector offers lucrative opportunities for the flowable hemostats market. The healthcare industry has been encountering a rapid transformation in recent years. Various countries across the globe have favored advanced technologies in healthcare. With the need for better healthcare facilities, Technology-Enabled Care (TEC) solutions are being referred to in the healthcare systems, especially in emerging economies. Some of the primary factors, such as rising incidences of chronic illnesses, an increase in the aging population, and pediatric care, are helping boost the growth of the healthcare industry. With rising technical procedures, the effectiveness of topical hemostats may help improve clinical outcomes. Thus, the ideal topical hemostats would offer authentic and prompt bleeding control. Such significant growth in the number of hospitals and surgical centers demands high adoption of flowable hemostat products, ultimately offering lucrative growth opportunities for the market's growth during the coming years.
Europe Flowable Hemostats Market Overview
The Europe market for flowable hemostats is spread across Germany, the UK, France, Italy, Spain, and the Rest of Europe. This regional market is expected to witness a steady growth rate of 7.3% from 2022 to 2028 due to the rise in the number of surgical procedures, increasing government initiatives, growing healthcare expenditure, and several other factors. Germany has some specific medical facilities and trained physicians to treat patients worldwide. Besides, the country has the most advanced medical training facilities, and doctors are required to undergo extensive education, residency, and practice. As per the study obtained from the German Federal Statistical Office, the country had nearly 951,936 hospital staff and approximately 1,903 hospitals in 2020, which is expected to increase the number of surgeries in the country over the coming years. The growing number of surgical procedures is a crucial factor behind the rise in the hemostats market in Germany. For instance, according to the German Society for Thoracic and Cardiovascular Surgery (GSTCVS), around 161,817 procedures were registered in 2019 across the country, out of which 92,809 were cardiac surgeries. Furthermore, Germany is the largest medical technology market and ranks third internationally. Approximately 11,000 medical devices are manufactured in the country, and two-thirds of its sales of medical devices were produced outside its domestic market. Germany is home to more than 30 dedicated cluster networks dedicated to innovative medical technology. The German Government's national high-tech strategy 2020 developed as a broad, interdepartmental advance strategy. Thus, factors, such as the growing number of hospitals and the rise in the number of surgeries, are likely to boost this market during the forecast period.
Europe Flowable Hemostats Market Revenue and Forecast to 2028 (US$ Million)
Europe Flowable Hemostats Market Segmentation
The Europe flowable hemostats market is segmented into material, product, application, end user, and country.
Based on material, the Europe flowable hemostats market is bifurcated into bovine gelatin & porcine gelatin. The bovine gelatin segment held a larger share of the Europe flowable hemostats market in 2022.
In terms of product, the Europe flowable hemostats market is segmented into combination hemostats, passive hemostats, and active hemostats. The combination hemostats segment held the largest share of the Europe flowable hemostats market in 2022.
Based on application, the Europe flowable hemostats market is categorized into general surgery, cardiac surgery, vascular surgery, orthopedic surgery, neuro and spine surgery, and others. The general surgery segment held the largest share of the Europe flowable hemostats market in 2022.
Based on end user, the Europe flowable hemostats market is segmented into hospitals and clinics, ambulatory surgery centers, and others. The hospitals and clinics segment held the largest share of the Europe flowable hemostats market in 2022.
By country, the Europe flowable hemostats market is categorized into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe flowable hemostats market in 2022.
Baxter International Inc, Ethicon (Johnson & Johnson), Pfizer Inc, Teleflex Incorporated, 3-D Matrix Medical Technology, Biom'up, and Aegis Lifesciences are some of the leading companies operating in the Europe flowable hemostats market.